Effects of Human Leptin Replacement

The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2008 by University of Miami.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Information provided by:
University of Miami
ClinicalTrials.gov Identifier:
NCT00657605
First received: April 9, 2008
Last updated: April 14, 2008
Last verified: April 2008
  Purpose

This study will test the hypothesis that leptin contributes to the regulation of the dynamics of human endocrine function.


Condition Intervention Phase
Obesity
Metabolic Syndrome
Diabetes
Drug: Recombinant methionyl human leptin
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effects of Human Leptin Replacement

Resource links provided by NLM:


Further study details as provided by University of Miami:

Primary Outcome Measures:
  • Weight loss [ Time Frame: Before and every 6 months after treatment is initiated, from 2001 to 2010 ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Improvement of metabolic parameters [ Time Frame: Before and every 6 months after treatment is initiated, from 2001 to 2010 ] [ Designated as safety issue: Yes ]

Enrollment: 3
Study Start Date: June 2001
Estimated Study Completion Date: December 2010
Estimated Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
Three adult patients with congenital leptin deficiency.
Drug: Recombinant methionyl human leptin
Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
Other Names:
  • Metreleptin
  • r-metHuLeptin

Detailed Description:

Three separate, but complementary, specific aims, will elucidate the role of leptin in the regulation of (A) the human pituitary-adrenal axis, (B) the human pituitary-gonadal axis, and (C) the human pituitary-thyroid axis. These aims will be approached by a carefully designed, prospective clinical study of the rapidly-sampled dynamics of endocrine rhythms during the course of leptin-replacement treatment in the only three adult individuals identified in the world so far who are leptin-naive due to a functional leptin gene mutation. A study of leptin-naive subjects avoids all confounding factors and pitfalls, because the only bioactive leptin to which they will be exposed is the exogenously administered recombinant protein. Thus, this proposal will permit us to ascertain the endocrine effects of human leptin. The proposed studies will elucidate key aspects of human endocrine function and will give new insights on the role of leptin in human endocrine regulation.

We also propose to perform structural MRI scans (on and off leptin replacement) to test the association of the changes in brain tissue composition with leptin replacement, and to test how leptin influences regional brain function during the presentation of food-related stimuli (pictures of food), which we will present to the patients along with neutral pictures (e.g., landscapes). We will test how this possible effect on brain function will be related to food craving or hunger.

In yet another part of the study we will assess the kinetics of human recombinant leptin.

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Congenital leptin deficiency (these are only 3 adult individuals in the world that have been identified as leptin-naïve thus far).

Exclusion Criteria:

  • Pregnant, trying to become pregnant, breast-feeding an infant or sexually active women, not using contraception.
  • Subjects with hemoglobin levels below 12 g/dl.
  • Subjects whose body contains a ferromagnetic implanted device that might produce a safety hazard during fMRI.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00657605

Locations
United States, Florida
University of Miami Miller School of Medicine, Center on Pharmacogenomics
Miami, Florida, United States, 33136
Sponsors and Collaborators
University of Miami
Investigators
Principal Investigator: Julio Licinio, MD University of Miami
  More Information

Publications:

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Julio Licinio. MD, University of Miami
ClinicalTrials.gov Identifier: NCT00657605     History of Changes
Other Study ID Numbers: 20060282, 1ROIDK58851-01
Study First Received: April 9, 2008
Last Updated: April 14, 2008
Health Authority: United States: Food and Drug Administration

Keywords provided by University of Miami:
Congenital leptin deficiency
Obesity
Metabolic syndrome
Diabetes

Additional relevant MeSH terms:
Diabetes Mellitus
Obesity
Metabolic Syndrome X
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Insulin Resistance
Hyperinsulinism

ClinicalTrials.gov processed this record on July 20, 2014